Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eliezer Mendel Van Allen, M.D.

Title
Institution
Department
Address
Phone
Fax

Overview

Mentoring
Dissecting Genomic Determinants of Response to Platinum-based Chemotherapy in Advanced NSCLC and Colorectal Cancer
Part Time, 01/01/17 - 12/31/17
Transcriptomic Correlates of Response to Immune Checkpoint Therapies in Melanoma
Soma Weiss, 01/01/18 - 12/28/18
Expanding accessibility of a molecular oncology almanac for precision cancer medicine
Soma Weiss, 08/06/18 - 08/02/19
Genomic predictors of response to CTLA4 blockade in metastatic melanoma
Summer, 06/15/15 - 08/30/15
Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy
Summer, 02/01/16 - 12/31/16

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21CA242861 (VAN ALLEN, ELIEZER M) Jul 1, 2019 - Jun 30, 2021
    NIH
    A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions
    Role: Principal Investigator
  2. U01CA233100 (VAN ALLEN, ELIEZER M) Sep 19, 2018 - Aug 31, 2023
    NIH
    Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
    Role: Principal Investigator
  3. R01CA227388 (VAN ALLEN, ELIEZER M) Jun 1, 2018 - May 31, 2023
    NIH
    Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
    Role: Principal Investigator
  4. R01CA222574 (VAN ALLEN, ELIEZER M) Feb 1, 2018 - Jan 31, 2023
    NIH/NCI
    Molecular origins and evolution to chemoresistance in germ cell tumors
    Role: Principal Investigator
  5. R37CA222574 (VAN ALLEN, ELIEZER M) Feb 1, 2018 - Jan 31, 2023
    NIH
    Molecular origins and evolution to chemoresistance in germ cell tumors
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cheung ATM, Palapattu EL, Pompa IR, Aldrighetti CM, Niemierko A, Willers H, Huang F, Vapiwala N, Van Allen E, Kamran SC. Racial and ethnic disparities in a real-world precision oncology data registry. NPJ Precis Oncol. 2023 Jan 19; 7(1):7. PMID: 36658153; PMCID: PMC9852424.
    Citations:    
  2. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022 12; 28(12):2584-2591. PMID: 36526723.
    Citations:    Fields:    Translation:Cells
  3. Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. JAMA Oncol. 2022 Nov 23. PMID: 36416812; PMCID: PMC9685549.
    Citations:    Fields:    
  4. Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2022 Oct 18; JCO2102947. PMID: 36256912.
    Citations: 1     Fields:    
  5. Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 10; 10(10). PMID: 36252998; PMCID: PMC9577940.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  6. Zhou M, Ko M, Hoge AC, Luu K, Liu Y, Russell ML, Hannon WW, Zhang Z, Carrot-Zhang J, Beroukhim R, Van Allen EM, Choudhury AD, Nelson PS, Freedman ML, Taplin ME, Meyerson M, Viswanathan SR, Ha G. Patterns of structural variation define prostate cancer across disease states. JCI Insight. 2022 09 08; 7(17). PMID: 35943799; PMCID: PMC9536266.
    Citations:    Fields:    Translation:Humans
  7. Crowdis J, Balch S, Sterlin L, Thomas BS, Camp SY, Dunphy M, Anastasio E, Shah S, Damon AL, Ramos R, Sosa DM, Small IK, Tomson BN, Nguyen CM, McGillicuddy M, Chastain PS, He MX, Cheung ATM, Wankowicz S, Tewari AK, Kim D, AlDubayan SH, Dowdye A, Zola B, Nowak J, Manarite J, Gunn IH, Olson B, Lander ES, Painter CA, Wagle N, Van Allen EM. A patient-driven clinicogenomic partnership for metastatic prostate cancer. Cell Genom. 2022 Sep 14; 2(9). PMID: 36177448; PMCID: PMC9518748.
    Citations:    
  8. Carvalho FLF, Mossanen M, Van Allen EM, Mouw KW. Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73. Eur Urol. 2022 11; 82(5):e141-e142. PMID: 35945087.
    Citations:    Fields:    Translation:Humans
  9. Schiantarelli J, Pappa T, Conway J, Crowdis J, Reardon B, Dietlein F, Huang J, Stanizzi D, Carey E, Bosma-Moody A, Imamovic A, Han S, Camp S, Kofman E, Shannon E, Barletta JA, He MX, Liu D, Park J, Lorch JH, Van Allen EM. Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer. JCO Precis Oncol. 2022 08; 6:e2200183. PMID: 36075011; PMCID: PMC9489159.
    Citations:    Fields:    Translation:Humans
  10. Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, Siegmund S, Tewari AK, Nowak JA, Lindeman NI, Rana HQ, Choudhury AD, Pomerantz MM, Freedman ML, Van Allen EM, Taplin ME. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022 Aug; 6:e2200329. PMID: 36103646; PMCID: PMC9489164.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  11. Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022 08 01; 8(8):1160-1168. PMID: 35708671; PMCID: PMC9204620.
    Citations:    Fields:    
  12. Hantel A, Clancy DD, Kehl KL, Marron JM, Van Allen EM, Abel GA. A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. J Clin Oncol. 2022 12 01; 40(34):3907-3911. PMID: 35849792; PMCID: PMC9746763.
    Citations:    Fields:    
  13. Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, Tadros J, Ferretti AP, Liao S, Gurer C, Chen YH, Criscitiello S, Ricker CA, Dionne D, Rozenblatt-Rosen O, Uppaluri R, Haddad RI, Ashenberg O, Regev A, Van Allen EM, MacBeath G, Schoenfeld JD, Wucherpfennig KW. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022 08 04; 185(16):2918-2935.e29. PMID: 35803260; PMCID: PMC9508682.
    Citations:    Fields:    
  14. Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol. 2022 07; 6:e2100413. PMID: 35797509; PMCID: PMC9848556.
    Citations:    Fields:    Translation:Humans
  15. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. PMID: 35739269.
    Citations:    Fields:    
  16. Gil Del Alcazar CR, Trinh A, Aleckovic M, Rojas Jimenez E, Harper NW, Oliphant MUJ, Xie S, Krop ED, Lulseged B, Murphy KC, Keenan TE, Van Allen EM, Tolaney SM, Freeman GJ, Dillon DA, Muthuswamy SK, Polyak K. Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunol Res. 2022 06 03; 10(6):680-697. PMID: 35446942; PMCID: PMC9177779.
    Citations:    Fields:    Translation:HumansAnimals
  17. Hwang JH, Arafeh R, Seo JH, Baca SC, Ludwig M, Arnoff TE, Sawyer L, Richter C, Tape S, Bergom HE, McSweeney S, Rennhack JP, Klingenberg SA, Cheung ATM, Kwon J, So J, Kregel S, Van Allen EM, Drake JM, Freedman ML, Hahn WC. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. Elife. 2022 05 12; 11. PMID: 35550030; PMCID: PMC9135408.
    Citations: 1     Fields:    Translation:HumansCells
  18. Park HJ, Qin L, Bakouny Z, Krajewski KM, Van Allen EM, Choueiri TK, Shinagare AB. Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors. Oncologist. 2022 05 06; 27(5):389-397. PMID: 35348767; PMCID: PMC9074990.
    Citations:    Fields:    Translation:Humans
  19. Gillani R, Camp SY, Han S, Jones JK, Chu H, O'Brien S, Young EL, Hayes L, Mitchell G, Fowler T, Gusev A, Kamihara J, Janeway KA, Schiffman JD, Crompton BD, AlDubayan SH, Van Allen EM. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am J Hum Genet. 2022 06 02; 109(6):1026-1037. PMID: 35512711; PMCID: PMC9247831.
    Citations:    Fields:    Translation:HumansCells
  20. Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, He MX, Liu Y, Van Allen E, Sowalsky AG, Bhasin MK, Yuan X, Balk SP. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res. 2022 04 15; 82(8):1518-1533. PMID: 35131873; PMCID: PMC9018564.
    Citations: 1     Fields:    Translation:HumansCells
  21. Dietlein F, Wang AB, Fagre C, Tang A, Besselink NJM, Cuppen E, Li C, Sunyaev SR, Neal JT, Van Allen EM. Genome-wide analysis of somatic noncoding mutation patterns in cancer. Science. 2022 04 08; 376(6589):eabg5601. PMID: 35389777; PMCID: PMC9092060.
    Citations: 1     Fields:    Translation:HumansCells
  22. Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, Jänne PA. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2022 06; 17(6):779-792. PMID: 35331964.
    Citations: 2     Fields:    Translation:Humans
  23. Labaki C, Van Allen EM, Choueiri TK. Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2022 03 01; 10(3):274. PMID: 35131809.
    Citations:    Fields:    Translation:HumansCells
  24. Labaki C, Bakouny Z, Sonpavde G, Choueiri TK, Van Allen EM. Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. Eur Urol Oncol. 2022 12; 5(6):719-721. PMID: 35105532.
    Citations:    Fields:    
  25. Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, Van Allen EM, Takeda DY, Loda M, Wu CL, Taplin ME, Garraway LA, Boehm JS, Huang FW. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022 04; 82(5):584-597. PMID: 35084050; PMCID: PMC8887817.
    Citations:    Fields:    Translation:HumansCells
  26. Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan CL, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Mary Lee GS, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DYC, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190. PMID: 34986355; PMCID: PMC9127595.
    Citations: 2     Fields:    Translation:HumansCells
  27. Mossanen M, Carvalho FLF, Muralidhar V, Preston MA, Reardon B, Conway JR, Curran C, Freeman D, Sha S, Sonpavde G, Hirsch M, Kibel AS, Van Allen EM, Mouw KW. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol. 2022 05; 81(5):466-473. PMID: 34953602; PMCID: PMC9018481.
    Citations:    Fields:    Translation:Humans
  28. Kehl KL, Xu W, Gusev A, Bakouny Z, Choueiri TK, Riaz IB, Elmarakeby H, Van Allen EM, Schrag D. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. Nat Commun. 2021 12 15; 12(1):7304. PMID: 34911934; PMCID: PMC8674229.
    Citations:    Fields:    Translation:Humans
  29. De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS. Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight. 2021 12 08; 6(23). PMID: 34877933; PMCID: PMC8675196.
    Citations:    Fields:    Translation:HumansAnimals
  30. Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, Hari SN, Van Allen EM, Marchionni L, Umeton R, Loda M. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022 02; 20(2):202-206. PMID: 34880124; PMCID: PMC9127877.
    Citations: 1     Fields:    Translation:Humans
  31. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol. 2022 Mar; 81(3):243-250. PMID: 34863587; PMCID: PMC8891030.
    Citations: 4     Fields:    Translation:Humans
  32. Bekele RT, Samant AS, Nassar AH, So J, Garcia EP, Curran CR, Hwang JH, Mayhew DL, Nag A, Thorner AR, Börcsök J, Sztupinszki Z, Pan CX, Bellmunt J, Kwiatkowski DJ, Sonpavde GP, Van Allen EM, Mouw KW. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. J Clin Invest. 2021 11 15; 131(22). PMID: 34554931; PMCID: PMC8592548.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  33. Kamran SC, Xie J, Cheung ATM, Mavura MY, Song H, Palapattu EL, Madej J, Gusev A, Van Allen EM, Huang FW. Tumor Mutations Across Racial Groups in a Real-World Data Registry. JCO Precis Oncol. 2021 11; 5:1654-1658. PMID: 34994651.
    Citations:    Fields:    Translation:Humans
  34. Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open. 2021 11 01; 4(11):e2133205. PMID: 34748007; PMCID: PMC8576580.
    Citations: 2     Fields:    Translation:Humans
  35. Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Alaiwi SA, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrisey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775. PMID: 34599169; PMCID: PMC8486778.
    Citations: 9     Fields:    Translation:HumansCells
  36. Reardon B, Moore ND, Moore NS, Kofman E, AlDubayan SH, Cheung ATM, Conway J, Elmarakeby H, Imamovic A, Kamran SC, Keenan T, Keliher D, Konieczkowski DJ, Liu D, Mouw KW, Park J, Vokes NI, Dietlein F, Van Allen EM. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nat Cancer. 2021 10; 2(10):1102-1112. PMID: 35121878; PMCID: PMC9082009.
    Citations: 2     Translation:Humans
  37. Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, AlDubayan SH, Salari K, Kregel S, Richter C, Arnoff TE, Park J, Hahn WC, Van Allen EM. Biologically informed deep neural network for prostate cancer discovery. Nature. 2021 10; 598(7880):348-352. PMID: 34552244; PMCID: PMC8514339.
    Citations: 10     Fields:    Translation:Humans
  38. Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563. PMID: 34548479; PMCID: PMC8455578.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  39. Tewari AK, Cheung ATM, Crowdis J, Conway JR, Camp SY, Wankowicz SA, Livitz DG, Park J, Lis RT, Bosma-Moody A, He MX, AlDubayan SH, Zhang Z, McKay RR, Leshchiner I, Brown M, Balk SP, Getz G, Taplin ME, Van Allen EM. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021 09 07; 36(10):109665. PMID: 34496240.
    Citations: 2     Fields:    Translation:Humans
  40. Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110. PMID: 34433812.
    Citations: 1     
  41. Gurjao C, Zhong R, Haruki K, Li YY, Spurr LF, Lee-Six H, Reardon B, Ugai T, Zhang X, Cherniack AD, Song M, Van Allen EM, Meyerhardt JA, Nowak JA, Giovannucci EL, Fuchs CS, Wu K, Ogino S, Giannakis M. Discovery and Features of an Alkylating Signature in Colorectal Cancer. Cancer Discov. 2021 10; 11(10):2446-2455. PMID: 34140290; PMCID: PMC8487940.
    Citations: 7     Fields:    Translation:Humans
  42. Hamid AA, Huang HC, Wang V, Chen YH, Feng F, Den R, Attard G, Van Allen EM, Tran PT, Spratt DE, Dittamore R, Davicioni E, Liu G, DiPaola R, Carducci MA, Sweeney CJ. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021 09; 32(9):1157-1166. PMID: 34129855; PMCID: PMC8463957.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  43. Gillani R, Seong BKA, Crowdis J, Conway JR, Dharia NV, Alimohamed S, Haas BJ, Han K, Park J, Dietlein F, He MX, Imamovic A, Ma C, Bassik MC, Boehm JS, Vazquez F, Gusev A, Liu D, Janeway KA, McFarland JM, Stegmaier K, Van Allen EM. Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. Cancer Res. 2021 08 01; 81(15):3971-3984. PMID: 34099491; PMCID: PMC8338889.
    Citations:    Fields:    Translation:Humans
  44. Kehl KL, Groha S, Lepisto EM, Elmarakeby H, Lindsay J, Gusev A, Van Allen EM, Hassett MJ, Schrag D. Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. JCO Clin Cancer Inform. 2021 06; 5:622-630. PMID: 34097438; PMCID: PMC8240790.
    Citations:    Fields:    Translation:Humans
  45. Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, Sahu A, Mei S, Miao B, Sharova T, Alvarez-Breckenridge C, Stocking JH, Kim T, Fadden R, Lawrence D, Hoang MP, Cahill DP, Malehmir M, Nowak MA, Brastianos PK, Lian CG, Ruppin E, Izar B, Herlyn M, Van Allen EM, Nathanson K, Flaherty KT, Sullivan RJ, Kellis M, Sorger PK, Boland GM. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992. PMID: 33941922; PMCID: PMC8474080.
    Citations: 9     Fields:    Translation:HumansCells
  46. Berchuck JE, Zhang Z, Silver R, Kwak L, Xie W, Lee GM, Freedman ML, Kibel AS, Van Allen EM, McKay RR, Taplin ME. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. Eur Urol. 2021 09; 80(3):295-303. PMID: 33888356.
    Citations: 3     Fields:    Translation:HumansCells
  47. McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021 07 01; 27(13):3610-3619. PMID: 33849963; PMCID: PMC8254786.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  48. Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Cañadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Jänne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 08; 11(8):1952-1969. PMID: 33707236; PMCID: PMC8338750.
    Citations: 12     Fields:    Translation:HumansAnimals
  49. Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):649-661.e5. PMID: 33711272.
    Citations: 51     Fields:    Translation:Humans
  50. He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433. PMID: 33664492; PMCID: PMC7960507.
    Citations: 23     Fields:    Translation:HumansCells
  51. Van Allen EM, Choueiri TK. Dissecting the immunogenomic biology of cancer for biomarker development. Nat Rev Clin Oncol. 2021 03; 18(3):133-134. PMID: 33299070.